Related Experiment Video
Updated: Jun 21, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Further evidence that methergoline is a central 5-hydroxytryptamine receptor blocking agent
K Fuxe1, S O Ogren, L F Agnati
1Department of Histology, Karolinska Institutet, Stockholm, Sweden.
Abstract:
The effects of methergoline were studied on [5-(3)H]hydroxytryptamine ([5-(3)H]HT) and [d-(3)H]lysergic acid diethylamide ([d-(3)H]LSD) binding in rat cerebral cortex and on a behaviour dependent upon 5-HT receptor activity. Methergoline had a high affinity for both d-LSD binding sites and 5-HT binding sites, the affinity being 5 times higher for the d-LSD binding site. Methergoline also blocked the 5-hydroxytryptophane (5-HTP) and d-LSD induced head twitches in mice being 4 times more efficient in blocking 5-HTP induced head twitches than d-LSD induced head twitches. The present results give evidence that methergoline is a postsynaptic 5-HT receptor blocking agent, an action probably related to its ability to bind to the antagonist site of the postsynaptic 5-HT receptor.
Related Concept Videos
Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Antidepressant Drugs: MAOIs and Other Agents
Drugs Affecting Neurotransmitter Release or Uptake
